ASPSCR1 and rhabdomyosarcoma: The positive rate of PAX3–FOXO1 was 88.6% (31/35) in alveolar rhabdomyosarcoma, EWSR1–FLI1 was 63% (17/27) in pPNET, SYT–SSX was 95.4% in SS (62/65), ASPSCR1–TFE3 was 100% in ASPS (10/10), FUS–DDIT3 was 80% in MLPS (4/5), and COL1A1–PDGFB was 66.7% in DFSP (8/12).